Menu Search
Equities

NeuroScientific Biopharmaceuticals Ltd

NSB:ASX

NeuroScientific Biopharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.039
  • Today's Change0.00 / 0.00%
  • Shares traded113.67k
  • 1 Year change-51.85%
  • Beta0.1617
Data delayed at least 20 minutes, as of Sep 18 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year NeuroScientific Biopharmaceuticals Ltd had revenues fall -52.76% from 5.06m to 2.39m, though the company grew net income from a loss of 1.07m to a gain of 324.21k.
Gross margin--
Net profit margin13.56%
Operating margin13.98%
Return on assets6.04%
Return on equity6.46%
Return on investment6.46%
More ▼

Cash flow in AUDView more

In 2024, NeuroScientific Biopharmaceuticals Ltd did not generate a significant amount of cash. However, the company earned 44.25k from its operations for a Cash Flow Margin of 1.85%. In addition the company used 1.82k on investing activities and also paid in financing cash flows.
Cash flow per share0.0029
Price/Cash flow per share13.57
Book value per share0.037
Tangible book value per share0.0343
More ▼

Balance sheet in AUDView more

NeuroScientific Biopharmaceuticals Ltd appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio58.87
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.